Drug class
Endothelin Receptor Antagonists clinical trials
A class of medicines: the studies that test any of its 16 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the endothelin receptor antagonists studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Sitaxentan sodium
- 2
- Nebentan potassium
- 2
- Avosentan
- 1
Studies by the year they started
323 studies that test it; most in 2008 (27); 1 more planned to start later
| Year | Studies |
|---|---|
| 1998 | 1 |
| 1999 | 1 |
| 2001 | 6 |
| 2002 | 4 |
| 2003 | 16 |
| 2004 | 8 |
| 2005 | 9 |
| 2006 | 19 |
| 2007 | 16 |
| 2008 | 27 |
| 2009 | 16 |
| 2010 | 21 |
| 2011 | 21 |
| 2012 | 8 |
| 2013 | 13 |
| 2014 | 10 |
| 2015 | 14 |
| 2016 | 9 |
| 2017 | 11 |
| 2018 | 17 |
| 2019 | 6 |
| 2020 | 13 |
| 2021 | 11 |
| 2022 | 12 |
| 2023 | 6 |
| 2024 | 9 |
| 2025 | 10 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 201 · Other 127
Actelion (67) · Idorsia Pharmaceuticals Ltd. (25) · AstraZeneca (22) · Gilead Sciences (17) · Pfizer (11) · GlaxoSmithKline (8) · Travere Therapeutics, Inc. (7) · University of Edinburgh (6)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 328
- dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized EvaluationNot yet recruitingPhase 2University Medical Center GroningenNCT06072326Written as SC0062 strength 10mg
- Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgANRecruitingPhase 3Novartis PharmaceuticalsNCT07498335Written as Drug: Atrasentan
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyNot yet recruitingPhase 3Novartis PharmaceuticalsNCT07850752Written as atrasentan
- : Vascular Function in Health and DiseaseRecruitingPhase 1D. Walter WrayNCT02966665Written as BQ-123
- A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other OptionRecruitingPhase 3ActelionNCT05179876Written as Macitentan
- Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)Not yet recruitingPhase 4University of Illinois at ChicagoNCT07820995Written as atrasentan
- Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated ProteinuriaRecruitingPhase 1Brigham and Women's HospitalNCT07224776Written as sparsentan
- A Study Evaluating Aprocitentan Tablets(SYH9108) for the Treatment of Resistant HypertensionNot yet recruitingPhase 3CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.NCT07635914Written as Aprocitentan tablets(SYH9108)
- A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A NephropathyRecruitingPhase 2University of LeicesterNCT04663204Written as Sparsentan
- COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy in PAH With Cardiovascular ComorbiditiesRecruitingPhase 3Assistance Publique - Hôpitaux de ParisNCT07245680Written as Ambrisentan
- Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesRecruitingPhase 2Travere Therapeutics, Inc.NCT05003986Written as Sparsentan
- Bosentan in the Treatment of Giant Cell ArteritisNot yet recruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT06957002Written as Bosentan
- Endothelin-1 Receptor Blockade in Resistant HypertensionRecruitingPhase 2University Hospital, RouenNCT04388124Written as Bosentan
- Efficacy and Mechanisms of Macitentan for Non-Coronary Obstructive AnginaRecruitingEarly Phase 1China-Japan Friendship HospitalNCT07392281Written as Macitentan 10 mg tablet, once daily.
- Dapagliflozin and Endothelin Receptor Antagonism in Large Vessel Vasculitis (DERAIL-LVV)RecruitingPhase 2University of EdinburghNCT06887062Written as Bosentan and dapagliflozin
- Comparison of Sequential to Initial Combination Therapy in PAHRecruitingNot applicableSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT06968962Written as Ambrisentan
- Ambrisentan for Early Low-Risk Pulmonary Arterial HypertensionNot yet recruitingNot applicableNanjing First Hospital, Nanjing Medical UniversityNCT06987097Written as Ambrisentan
- A Study of SC0062 Capsule for the Treatment of IgA Nephropathy with ProteinuriaRecruitingPhase 3Biocity Biopharmaceutics Co., Ltd.NCT06819826Written as SC0062 strength 10mg
- Evaluation of the Efficacy of MACitentan in the Treatment of CoronaryMICrovascular Angina (MACMIC)RecruitingEarly Phase 1China-Japan Friendship HospitalNCT06811831Written as Macitentan 10 mg tablet, once daily.
- Efficacy of Endothelin Receptor Antagonism in Coronary Artery SpasmEnrolling by invitationPhase 2/3Radboud University Medical CenterNCT06432452Written as Endothelin Receptor Antagonist
See all 328 studies that test one of the endothelin receptor antagonists →
Codes
What other systems call Endothelin Receptor Antagonists · ClinicalTrials.gg INT008983
- MeSH (NLM) D065128Endothelin Receptor AntagonistsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D065128 | Endothelin Receptor Antagonists | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.